​On September 19, NanoVation Therapeutics (NanoVation Corporation, headquartered in Canada) announced a multi-year R&D partnership with Novo Nordisk, To jointly advance the development of innovative genetic medicine for cardiac metabolic diseases and rare diseases.

Canada's ability to stand out in the highly competitive global medical device market is inseparable from Canada's rich educational resources and talent pool.

"We have avoided a global economic recession," said Christina Georgieva, Managing Director of the International Monetary Fund. However, the situation is still not optimistic. The global economic growth forecast for 2024 remains at 3.2%. In 2023, it is also 3.2%, and it is expected to remain at 3.2% by 2025. This is significantly lower than the usual expectation of about 4% in the past. Georgieva has warned that this will be a "disappointing decade".

According to the latest released data, Canada experienced a trade deficit of CAD 2.28 billion in March, far from the market's expected surplus of CAD 1.5 billion, and also far below the previous surplus of CAD 1.39 billion. This result reflects the new challenges encountered in Canada's economic recovery, particularly in the context of rising global energy prices and persistent supply chain issues.

The global market for chromatography accessories and consumables is expected to grow from $4.4 billion in 2022 to $6.5 billion in 2027, with a compound annual growth rate of 8%.

From March 8 to 10, 2024, the second International Forum on Corneal and Ocular Surface Diseases was held in Changsha. The forum brought together more than 400 experts and scholars from around the world to share the latest research results on topics such as dry eye, corneal surgery, pterygium, keratoconus, and eye bank through more than 60 academic reports.